S867
MULTIPLE MECHANISMS OF KRAS ACTIVATION IN TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA

E. Vendramini1, R. Bomben1, F. Serra1, F. Pozzo1, D. Benedetti1, F.M. Rossi1, G. Del Poeta1, F. Zaja1, A. Chiarenza1, G. Pozzato2, V. Gattei1, A. Zucchetto1

1Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, 2Clinica Ematologica, Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, 3Division of Hematology, Ferrarotto Hospital, Catania, 4Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy

Background: Trisomy 12 (Tri12) chronic lymphocytic leukemia (CLL) identifies a cytogenetic subset with a peculiar clinical behavior (Bulun et al, Haematologica, 2017) and specific biological features, including high frequency of stabilizing NOTCH1 mutations (NOTCH1-mut) (Rossi et al, Blood, 2013). Moreover, KRAS and its transcriptional regulator HNRPAP1, key components of Ras-Raf-MEK-ERK pathway are both hosted in the trisomic chromosome 12.

Aims: To investigate the role of KRAS expression and/or activation in Tri12 and NOTCH1-mut CLL.

Methods: Tri12 was assessed by FISH. NOTCH1 and KRAS mutations were assessed by either Sanger or NGS. QRT-PCR and western blot were employed to evaluate HNRPAP1 and KRAS expression and downstream signaling in primary CLL or CLL cell line models. Active GTP-bound RAS pull-down was performed by Raf1 BDR agarose beads assay. CI and MEC-1 cell lines were used as human in vitro model of Tri12 NOTCH1-mut CLL and non-Tri12 NOTCH1-wild type (wt) CLL, respectively. Mann-Whitney test, unpaired t-test or Chi-Square test were used to compare differences between groups.

Results: KRAS transcript was analyzed in 215 cases purposely enriched in Tri12 (118) and NOTCH1-mut (121). As shown in Figure 1 A, Tri12 were characterized by higher KRAS level in the context of NOTCH1-wt CLL (p=0.04); conversely, no differences in KRAS expression were found between Tri12 and non-Tri12 in the context of NOTCH1-mut CLL cases, which however expressed higher KRAS transcript compared to NOTCH1-wt CLL (p=0.008). Consistently, KRAS protein level was higher in Tri12 vs. non-Tri12 in the context of NOTCH1-wt CLL (Figure 1 B). A gene expression profiling identified HNRNPA1 as the top ranked gene among MYC target genes upregulated in NOTCH1-mut vs. NOTCH1-wt CLL. Accordingly, higher HNRPAP1 levels were found by QRT-PCR in additional 41 NOTCH1-mut vs. 47 NOTCH1-wt CLL samples (p=0.003, Figure 1 C,D) without differences between Tri12 (42) and non-Tri12 (46) CLL. In line with a KRAS transcriptional activation mediated by NOTCH1-MYC-HNRPAP1 axis, higher MYC, HNRPAP1 and KRAS protein levels were found in the Tri12 NOTCH1-mut CI cell line when compared to the non-Tri12 NOTCH1-wt MEC-1 cells. Furthermore, higher levels of active GTP-bound KRAS and higher phosphorylation levels of MEK and ERK were found in CI cells (Figure 1 E,F,G), supporting the hypothesis of sustained Ras-Raf-MEK-ERK signaling in Tri12 and NOTCH1-mut CLL. Finally, analysis of KRAS genomic aberrations revealed higher mutation incidence in Tri12 CLL (10/77, 13%) compared to non-Tri12 CLL (2/68, 2.9%, p=0.03). Altogether, these data foster the hypothesis of multiple mechanisms of KRAS overexpression/activation occurring in Tri12 CLL via the NOTCH1-MYC-HNRPAP1 axis in NOTCH1-mut cases, or due to a higher incidence of KRAS mutations or an overexpression of KRAS by the super-numerary chromosome 12 (Figure 1 H).

Summary/Conclusion: Our data, by describing a synergism between Tri12, NOTCH1-mut and KRAS in boosting KRAS expression and activity in CLL, indicate the Tri12 subset as particularly addicted to the Ras-Raf-MEK-ERK signaling pathway and likely to benefit of ERK/MEK inhibitors, as recently emphasized (Dietrich et al, J Clin Invest, 2018).

S868
REGULATION OF HIF-1A IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET


1Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 2Department of Oncology, University of Torino, Torino, 3Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy, 4Department of Hematology, Hematology Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland, 5Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, 6Hematology Day Service, Oncology SOC, Hospital Cardinale Mausoleo, Asti, 7Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 8Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, 9Department of Hematology, Catholic University of Sacred Heart, 10Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, 11Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Roma, 12Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, 13Ematology Unit, ASO Santa Croce e Carle, Cuneo, Italy

Background: Treatment of high-risk chronic lymphocytic leukemia (CLL) patients remains an unmet clinical need. Disease aggressiveness can be ascribed to intrinsic features of the tumor cells (i.e. TP53 disruption) and to the interaction of CLL cells with stromal cells (SC) of the microenvironment. HIF-1α is a transcription factor implicated in cell adaptation to hypoxia and involved in the regulation of genes implicated in tumor progression. In CLL cells, the α subunit of HIF-1 (HIF-1α) is constitutively expressed even in normoxia and regulates the protective interactions that the leukemic cells establish with the microenvironment.

Aims: The aims of this study were to understand HIF-1α regulatory pathways in CLL cells from TP53 disrupted (TP53mut) and wild type (TP53wt) patients, and to evaluate the ability of HIF-1α inhibition to exert synergistic cytotoxic effects in combination with fludarabine and ibrutinib.

Methods: Del(17p) in CLL cells was assessed by fluorescence in situ hybridization and the presence of TP53 gene mutations was evaluated by Sanger sequencing. CLL patients with mutation of the TP53 gene, or >40% del(17p) in the absence of TP53 mutation, were included in the TP53 mut subset. Patients with <10% del(17p) and without TP53 mutation were considered TP53+. In selected experiments, CLL cells were cultured in the presence or absence of M-201204 SC, and exposed to PD98059, Y27632, LY249002, BAY87-2243, F-ara-A or ibrutinib. Culture conditions were 21% (normoxia) or 5% O2, 2% CO2 at 37°C. Ras, ERK1/2, Akt, HIF-1α, Elk1 and pVHL expression was evaluated by Western Blot. Ras, HIF-1α and RhoA kinase activity was measured by specific immunoassays. HIF-1A, p21 and ENO1 gene expression was assessed by RT-PCR. Cell viability was analyzed by AnnexinV/protopium iodide co-immunostaining.
Results: We found that primary CLL cells from patients carrying TP53 abnormalities (TP53α CLL cells) had constitutively higher transcriptional activity and expression levels of the α subunit of HIF-1 compared to CLL cells isolated from TP53α samples (TP53α CLL cells). HIF-1α upregulation detected in the TP53α subset was due to a reduced expression of the HIF-1α ubiquitin ligase von Hippel-Lindau protein (pVHL) and more active PI3K/Akt and Ras/ERK1-2 signalling pathways. Hypoxia and SC further enhanced the accumulation in both TP53α and TP53α+ CLL cells. Hypoxia-mediated HIF-1α upregulation was due to a decreased pVHL expression and to the activation of PI3K/Akt and Ras/ERK1-2 signalling pathways. SC did not affect pVHL expression, but induced an increased activity of Ras/ERK1-2, Rho/RhoA kinase and PI3K/Akt pathways, leading to HIF-1α accumulation. Interestingly, in vitro fludarabine-resistant CLL cells were mostly TP53α and expressed significantly higher levels of HIF-1α mRNA compared to fludarabine-sensitive cells. The HIF-1α inhibitor BAY87-2243 reversed the constitutive fludarabine resistance of leukemic cells isolated from patients carrying TP53 abnormalities, and counteracted the fludarabine resistance induced by SC. BAY87-2243 also elicited a strongly synergistic cytotoxic effect in combination with ibrutinib.

Summary/Conclusion: Overall, our data indicate that HIF-1α is overexpressed in CLL cells, especially in the presence of TP53 abnormalities, and is susceptible of positive regulation by hypoxia and SC. From the translational standpoint, HIF-1α can be regarded as a crucial target whose inhibition warrants further evaluation, also in combination with currently available therapies.

**S669**

**IBRUTINIB DOES NOT SUPPRESS CLONAL EVOLUTION IN HIGH RISK CHRONIC LYMPHOCYOTIC LEUKEMIA**


1Institute of Oncology Research, Bellinzona, Switzerland; 2University of Eastern Piedmont, Novara, Italy; 3Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; 4Niguarda Cancer Center, Niguarda Hospital, Milano, Italy; 5Pollicitico Gemelli Foundation, Catholic University of the Sacred Heart, Roma, Italy; 6Pollicitico Universitario Ospedale di Circolo e Fondazione Macchi, Varese, Italy; 7IRCCS San Raffaele Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy; 8Eugenio Hospital and University of Tor Vergata, Roma, Italy; 9Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 10University of Udine, Udine, Italy; 11Centro di Riferimento Oncologico, IRCCS, Aviano, Aviano, Italy, Italy; 12Division of Haematology and Central Haematology Laboratory, Cantonal Hospital Lucerne, Luzern, Switzerland; 13Department of Medicine and Surgery, Hematology, University of Insubria, Varese, Italy; 14Institute of Hematology, Università Cattolica del Sacro Cuore, Roma, Italy, Italy; 15Department of Hematology, University Hospital Basel, Basel, Switzerland

**Background:** The B-cell receptor (BCR) is one of the most important surface molecules that CLL cells use to gain oncogenic signals from the microenvironment. The critical role of BCR signaling for the pathogenesis of CLL is supported by the therapeutic success of ibrutinib, a targeted agent that disrupts the BCR pathway. Beside microenvironment-promoted oncogenic signals, the biology of CLL is also driven by molecular lesions and clonal evolution, that mark CLL progression and treatment resistance. The interconnection between microenvironment-promoted oncogenic signals and clonal evolution has been postulated in CLL but never proven because of the lack of suitable *ex vivo* models.

**Aims:** Ibrutinib allows the unprecedented opportunity of assessing the contribution of BCR to cancer clonal evolution directly *in vivo* in patients.

**Methods:** The OSI-EMA-001 study (NCT02827617) is an observational, non-interventional, multicenter study consisting in the prospective and longitudinal collection of peripheral blood samples and clinical data from high risk CLL patients treated with ibrutinib mono therapy. Tumor DNA derived from sorted CLL cells (purity >99%) and germline DNA derived from sorted T cells were used for somatic mutation identification by CAP identification in both TP53α and TP53α+ CLL cells, deep next generation. A gene panel including 133 genes recurrently mutated in mature B-cell tumors or targeted by the aberrant somatic hypermutation process, was used. The number of the libraries loaded in the NexSeq500 sequencer (Illumina) was tailored at obtaining at least a coverage >2000x in >80% of the regions of interest. A stringent bioinformatic pipeline was applied to suppress the background noise allowing to call variants with a sensitivity of 3x10⁻³. To track clonal trajectories across serial samples, we first measured the variant allele fraction (VAF) of all mutations identified across the different timepoints per patient. VAFs were transformed to cancer cell fractions (CCF) using the ABSOLUTE tool. For each patient, we compared the clonal composition of the baseline sample with all the available longitudinal samples (up to 72 weeks of therapy).

**Results:** The study cohort comprised 31 high risk CLL patients, including 15 treatment naive, 16 relapsed, 80% IGHV unmutated, 42% 17p deleted and 53% TP53 mutated (Figure 1A). Median duration of ibrutinib treatment was 45 weeks (range 24-72 weeks). Overall, 285 individual mutations were longitudinally discovered and monitored across a total of 119 sequential timepoints collected during ibrutinib treatment. Significant changes in CCF over time, defined as a FDR adjusted p value of <0.1 for change in CCF >0.1 in the largest rising or falling clone was observed in 21/31 (67.7%) cases (Figure 1B), a proportion that is superimposable to the clonal evolution rate previously documented in CLL treated with chemoinmunotherapy. Clonal evolution appeared to be puzzled and involved different genes without a stereotypic targeting (Figure 1C). Consistently, none of the main driver gene mutations was homogeneously selected or suppressed by ibrutinib. Clonal evolution rate neither associated with IGHV or TP53 mutation status (Figure 1D), nor changed over time (Figure 1E).

**Figure 1.**

**Summary/Conclusion:** Our results suggest that clonal evolution, a known pathogenic mechanism of progressive CLL: i) is not abrogated by ibrutinib; and ii) is quantitatively similar, but qualitatively different, than clonal evolution under chemoinmunotherapy, without specific pathways being targeted.

**S870**

**RITUXIMAB INDUCES A PRO-INFLAMMATORY MICROENVIRONMENT THAT INCREASES NOTCH1 SIGNALLING IN CHRONIC LYMPHOCYTOCYTIC LEUKAEMIA CELLS**

J. Edelmann1,2, K. Holzmann2, J. G. Gribben1

1Centre for Haema-Oncology, Barts Cancer Institute, London, United Kingdom; 2Genomics Core Facility, Ulm University, Ulm, Germany

**Background:** The addition of the anti-CD20 monoclonal antibody (mAb) rituximab to chemotherapy improves responses in almost all chronic lymphocytic leukaemia (CLL) patients, with the exception of those having NOTCH1 mutations. NOTCH1 is a cell surface receptor releasing its intracellular domain (NICD1) after two ligand-induced cleavage steps performed by metalloproteases and γ-secretase. NICD1 acts as transcription factor and NOTCH1 mutations in CLL lead to longer lasting transcription factor activity.

**Aims:** To understand the relationship between rituximab and NOTCH1, we studied the effects rituximab treatment has on NOTCH1 signalling.

**Methods:** Freshly isolated peripheral blood mononuclear cells (PBMCs) from CLL patients attending St. Bartholomew’s Hospital, London were enriched for CD19+ cells and treated with rituximab. Whole protein lysates were previously documented in CLL treated with chemoinmunotherapy. Clonal evolution appeared to be puzzled and involved different genes without a stereotypic targeting (Figure 1C). Consistently, none of the main driver gene mutations was homogeneously selected or suppressed by ibrutinib. Clonal evolution rate neither associated with IGHV or TP53 mutation status (Figure 1D), nor changed over time (Figure 1E).

**Figure 1.**

**Summary/Conclusion:** Our results suggest that clonal evolution, a known pathogenic mechanism of progressive CLL: i) is not abrogated by ibrutinib; and ii) is quantitatively similar, but qualitatively different, than clonal evolution under chemoinmunotherapy, without specific pathways being targeted.